382 CARDIOVASCULAR OUTCOMES WITH ANTI-HYPERTENSIVE THERAPY IN TYPE 2 DIABETES
作者
George Jerums,Sianna Panagiotopoulos,Elif Ilhan Ekinci,Karey Cheong,Richard J. MacIsaac
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins] 日期:2012-09-01卷期号:30 (Supplement 1): e112-e113
标识
DOI:10.1097/01.hjh.0000420231.52996.42
摘要
Background: Relative cardiovascular (CV) risk reduction (RRR) is largely independent of attained systolic blood pressure (SBP) 1. How this translates to absolute risk reduction (ARR) in diabetes is not clear. Methods: We have compared five year CV outcomes (fatal and non-fatal myocardial infarct or stroke) in ten studies of intensive versus moderate or active versus placebo therapy in subjects with type 2 diabetes and attained SBP < or ≥140 mmHg. Results: Attained SBP ≥140 mmHg occurred in five early studies (HOT n = 1001, UKPDS n = 1148, SHEP n = 583, SYSTEUR n = 422, MICRO-HOPE n = 3377) and attained SBP < 140 mmHg occurred in five recent studies (ABCD-NT n = 480, ADVANCE n = 11,140, INVEST n = 4266, ACCORD n = 4733, ROADMAP n = 4447). In each study, ARR was calculated from group mean data and expressed as % change in CV events over five years per 10 mmHg decrease in attained SBP. In studies with attained SBP ≥140 mmHg, ARR was 13 ± 2.6% per 10 mmHg, and the number needed to treat (NNT) to prevent one event in five years was 8. In studies with attained SBP < 140 mmHg, ARR was 1.6 ± 1.9% per 10 mmHg (p = 0.0007), and NNT was 68.Conclusion: The marked decrease in ARR in studies with attained SBP < 140 mmHg occurred despite maintenance of RRR in 4/5 studies. Whether this is peculiar to diabetes requires further investigation. 1 Law MR, B M J 2009;338:1-9